Topic: How To Invest

Hi Pat: Can I have your view on Profound Medical? Thanks.

Article Excerpt

A: Profound Medical Corp., $1.41 symbol PRN on the TSX Venture Exchange (Shares outstanding: 39.5 million; Market cap: $55.7 million; www.profoundmedical.com), has developed what it believes is a unique procedure to treat prostate cancer. Called TULSA (Transurethral Ultrasound Ablation), this method uses magnetic resonance imaging and robot technology to hit cancerous tissue with high-intensity ultrasound. It does that without harming surrounding cells. In the process, that speeds up recovery times and limits side effects. The company began developing the TULSA system in 2010 based on research conducted by the Sunnybrook Health Sciences Centre in Toronto. The stock began trading on the Toronto Venture Exchange on June 8, 2015. To conduct its research and development activities, Profound is currently using up its cash at a rate of about $3.3 million a quarter. On March 31, 2016, its reserves held $17.0 million. That gives it enough cash to maintain its research spending for just over a year. The company has formed a strategic partnership with…